Breast cancer drug could help fight brain tumors

NCT ID NCT03122197

Recruiting now Disease control Sponsor: University of Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests whether letrozole, a drug normally used for breast cancer, can reach and concentrate in recurrent high-grade gliomas (aggressive brain tumors). About 39 adults will take letrozole pills daily along with standard temozolomide chemotherapy. Researchers will measure how much letrozole gets into the tumor and track side effects and survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letrozole (Femara) and Temozolomide (Temodar)
What this could lead to: If it works, this could point toward a new way to treat recurrent high-grade gliomas by combining letrozole with standard chemotherapy.
What could go wrong: This is a very early, small trial (39 people) focused on drug levels and safety, not yet on effectiveness. The drug may not reach tumors enough or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR

Contacts and locations

Locations

University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.